AngioDynamics Announces First Patient Enrolled in APEX-AV Study Assessing AlphaVac F18⁸⁵ PE System in Treatment of Pulmonary Embolism
APEX-AV is a single-arm Investigational Device Exemption study enrolling patients with confirmed acute, intermediate-risk PE at up to 20 hospital-based sites in
“We are excited to have the first patient enrolled in this important trial as we assess the performance of the AlphaVac F1885 System in patients with intermediate-risk pulmonary embolisms,” said
Pulmonary embolism can be a life-threatening condition and affects approximately 1 in 1,000 people in the
“I would like to congratulate
“We are privileged to have the first patient enrolled in this important PE trial using the AlphaVac F1885 System at
To facilitate patient enrollment for its APEX-AV Study,
“We are honored to be the partner of choice alongside
Viz RECRUIT may facilitate clinical trial enrollment by using artificial intelligence to identify eligible clinical trial candidates and connects the research team to the clinical care team — all in a secure, HIPAA-compliant environment. Viz.ai’s cloud-based technology broadens the recruitment funnel in both size and diversity by identifying existing patients at hub and spoke hospitals that are trial-eligible and screening patients as they are evaluated. This capability will allow for more efficient enrollment and streamline workflows and communication at APEX-AV Study sites.
Using artificial intelligence to automatically identify patients during clinical evaluation, Viz RECRUIT may enable real-time recruitment within the health system. Viz RECRUIT's ability to embed clinical research into the care continuum helps speed up enrollment rates which could lead to more timely completion of clinical trials and a faster path to market for life saving therapies.
Visit https://clinicaltrials.gov/ct2/show/NCT05318092 for more information about the APEX-AV Study.
Sources: *Jankowitz B. et al 2021,SNIS-E-022;
About the AlphaVac MMA F1885 System
The AlphaVac MMA F1885 System is an emergent first-line device that is currently cleared for the removal of thromboemboli from the venous system. The System includes an ergonomic handle, an 18F cannula with an 85-degree angle, an obturator, and a waste bag assembly. The APEX-AV Study was designed to provide safety and efficacy data for a clearance specific to PE. Risk information: https://bit.ly/Angio-risk-info
The AlphaVac MMA F1885 System when used for treatment of pulmonary embolism is an investigational device. Limited by
Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 200 million lives across 1,200+ hospitals and health systems in the US and
About The PERT Consortium™
The purpose of The PERT Consortium™ is to serve the general public by undertaking activities to advance the status of PE care and promote research in the treatment of pulmonary embolism. Specifically, the Consortium’s purpose is to:
Promote the adoption of the PERT model in healthcare institutions across
Expand the current body of scientific literature on the diagnosis and treatment of pulmonary embolism through the funding of scientific endeavors.
Educate the general public and healthcare professionals regarding pulmonary embolism diagnosis, treatment, and care.
By focusing solely on the entity of pulmonary embolism – its etiology, pathophysiology, prevention, management approach, outcomes of specific treatments, and follow-up pathways – it is the intention of the Consortium to increase awareness of treatment options available to patients with PE, to reduce its incidence worldwide, to improve health outcomes, and to positively influence the impact of this terrible disease.
The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.
1 Learn About Pulmonary Embolism. Lung.org. http://www.lung.org/lung-health-diseases/lung-disease-lookup/pulmonary-embolism/learn-about-pulmonary-embolism. Published 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221031005775/en/